VYNE reports FY2024 net loss $39.8M; cash $61.5M; repibresib Phase 2b data due mid-2025

VYNE Therapeutics Inc.

Cash & equivalents total $61.5M as of Dec 31, 2024; expected runway into 2H 2026.
Net loss for FY 2024 was $39.8M ($0.93 per share) vs $28.5M ($2.78 per share) in 2023.
R&D expenses doubled to $30.9M driven by Phase 2b repibresib and Phase 1a VYN202 trials.
Repibresib gel Phase 2b vitiligo top-line data expected mid-2025; fully enrolled ~180 subjects.
VYN202 Phase 1b psoriasis trial initiated; top-line results expected by year-end 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.